AVALO THERAPEUTICS INC (AVTX) Stock Fundamental Analysis

NASDAQ:AVTX • US05338F3064

14.26 USD
-0.14 (-0.97%)
At close: Feb 13, 2026
14.26 USD
0 (0%)
After Hours: 2/13/2026, 5:53:36 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

Overall AVTX gets a fundamental rating of 4 out of 10. We evaluated AVTX against 523 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for AVTX as it has an excellent financial health rating, but there are worries on the profitability. AVTX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • AVTX had negative earnings in the past year.
  • AVTX had a negative operating cash flow in the past year.
  • In the past 5 years AVTX always reported negative net income.
  • AVTX had a negative operating cash flow in each of the past 5 years.
AVTX Yearly Net Income VS EBIT VS OCF VS FCFAVTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M

1.2 Ratios

  • AVTX's Return On Assets of -79.77% is on the low side compared to the rest of the industry. AVTX is outperformed by 67.50% of its industry peers.
  • The Return On Equity of AVTX (-109.00%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -79.77%
ROE -109%
ROIC N/A
ROA(3y)-99.47%
ROA(5y)-109.74%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AVTX Yearly ROA, ROE, ROICAVTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

1.3 Margins

  • AVTX has a better Gross Margin (420.31%) than 99.62% of its industry peers.
  • AVTX's Gross Margin has improved in the last couple of years.
  • The Profit Margin and Operating Margin are not available for AVTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 420.31%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y36.21%
GM growth 5Y11.03%
AVTX Yearly Profit, Operating, Gross MarginsAVTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • AVTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, AVTX has more shares outstanding
  • AVTX has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for AVTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
AVTX Yearly Shares OutstandingAVTX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
AVTX Yearly Total Debt VS Total AssetsAVTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • AVTX has an Altman-Z score of -0.93. This is a bad value and indicates that AVTX is not financially healthy and even has some risk of bankruptcy.
  • AVTX has a Altman-Z score (-0.93) which is comparable to the rest of the industry.
  • There is no outstanding debt for AVTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.93
ROIC/WACCN/A
WACC12.3%
AVTX Yearly LT Debt VS Equity VS FCFAVTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

  • AVTX has a Current Ratio of 14.28. This indicates that AVTX is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Current ratio value of 14.28, AVTX belongs to the best of the industry, outperforming 90.63% of the companies in the same industry.
  • AVTX has a Quick Ratio of 14.28. This indicates that AVTX is financially healthy and has no problem in meeting its short term obligations.
  • AVTX has a Quick ratio of 14.28. This is amongst the best in the industry. AVTX outperforms 90.63% of its industry peers.
Industry RankSector Rank
Current Ratio 14.28
Quick Ratio 14.28
AVTX Yearly Current Assets VS Current LiabilitesAVTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 95.12% over the past year.
  • The Revenue for AVTX has decreased by -76.59% in the past year. This is quite bad
  • Measured over the past years, AVTX shows a very negative growth in Revenue. The Revenue has been decreasing by -42.05% on average per year.
EPS 1Y (TTM)95.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-75.2%
Revenue 1Y (TTM)-76.59%
Revenue growth 3Y-56.61%
Revenue growth 5Y-42.05%
Sales Q2Q%-100%

3.2 Future

  • The Earnings Per Share is expected to grow by 14.59% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 100.98% on average over the next years. This is a very strong growth
EPS Next Y96.23%
EPS Next 2Y40.31%
EPS Next 3Y25.45%
EPS Next 5Y14.59%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y100.98%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
AVTX Yearly Revenue VS EstimatesAVTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2029 2030 2031 2032 2033 100M 200M 300M
AVTX Yearly EPS VS EstimatesAVTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -2K -4K -6K

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for AVTX. In the last year negative earnings were reported.
  • Also next year AVTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AVTX Price Earnings VS Forward Price EarningsAVTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AVTX Per share dataAVTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10

4.3 Compensation for Growth

  • AVTX's earnings are expected to grow with 25.45% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.31%
EPS Next 3Y25.45%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for AVTX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AVALO THERAPEUTICS INC

NASDAQ:AVTX (2/13/2026, 5:53:36 PM)

After market: 14.26 0 (0%)

14.26

-0.14 (-0.97%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)03-18
Inst Owners77.78%
Inst Owner Change8.83%
Ins Owners3.45%
Ins Owner Change-3.01%
Market Cap258.53M
Revenue(TTM)192.00K
Net Income(TTM)-99.79M
Analysts86.25
Price Target35.06 (145.86%)
Short Float %18.79%
Short Ratio8.9
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-31.71%
Min EPS beat(2)-33.98%
Max EPS beat(2)-29.44%
EPS beat(4)1
Avg EPS beat(4)-485.44%
Min EPS beat(4)-1889.97%
Max EPS beat(4)11.62%
EPS beat(8)1
Avg EPS beat(8)-1992.39%
EPS beat(12)4
Avg EPS beat(12)-1320.52%
EPS beat(16)7
Avg EPS beat(16)-983.66%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.96%
PT rev (3m)6.47%
EPS NQ rev (1m)-6.46%
EPS NQ rev (3m)9.18%
EPS NY rev (1m)-2.66%
EPS NY rev (3m)-3.32%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1346.53
P/FCF N/A
P/OCF N/A
P/B 2.82
P/tB 3.19
EV/EBITDA N/A
EPS(TTM)-13.31
EYN/A
EPS(NY)-5.17
Fwd EYN/A
FCF(TTM)-2.88
FCFYN/A
OCF(TTM)-2.88
OCFYN/A
SpS0.01
BVpS5.05
TBVpS4.47
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -79.77%
ROE -109%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 420.31%
FCFM N/A
ROA(3y)-99.47%
ROA(5y)-109.74%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y36.21%
GM growth 5Y11.03%
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.28
Quick Ratio 14.28
Altman-Z -0.93
F-Score4
WACC12.3%
ROIC/WACCN/A
Cap/Depr(3y)52.94%
Cap/Depr(5y)33.74%
Cap/Sales(3y)2.92%
Cap/Sales(5y)2.34%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)95.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-75.2%
EPS Next Y96.23%
EPS Next 2Y40.31%
EPS Next 3Y25.45%
EPS Next 5Y14.59%
Revenue 1Y (TTM)-76.59%
Revenue growth 3Y-56.61%
Revenue growth 5Y-42.05%
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y100.98%
EBIT growth 1Y-82.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-63.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-63.93%
OCF growth 3YN/A
OCF growth 5YN/A

AVALO THERAPEUTICS INC / AVTX FAQ

Can you provide the ChartMill fundamental rating for AVALO THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 4 / 10 to AVTX.


What is the valuation status of AVALO THERAPEUTICS INC (AVTX) stock?

ChartMill assigns a valuation rating of 1 / 10 to AVALO THERAPEUTICS INC (AVTX). This can be considered as Overvalued.


How profitable is AVALO THERAPEUTICS INC (AVTX) stock?

AVALO THERAPEUTICS INC (AVTX) has a profitability rating of 2 / 10.